NeuroThera Labs Inc.
Neurothera Labs Inc. operates a clinical-stage pharmaceutical company. The company engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. Neurothera Labs Inc. was formerly known as Miza III Ventu… Read more
NeuroThera Labs Inc. (NTLX) - Total Liabilities
Latest total liabilities as of April 2025: CA$165.45K CAD
Based on the latest financial reports, NeuroThera Labs Inc. (NTLX) has total liabilities worth CA$165.45K CAD as of April 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NeuroThera Labs Inc. - Total Liabilities Trend (2022–2025)
This chart illustrates how NeuroThera Labs Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NeuroThera Labs Inc. Competitors by Total Liabilities
The table below lists competitors of NeuroThera Labs Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ECR Minerals plc
LSE:ECR
|
UK | GBX81.15K |
|
European Energy Metals Corp.
OTCQB:EUEMF
|
USA | $144.63K |
|
ENERGY METALS
MU:E9M
|
Germany | €188.98K |
|
Eagle Royalties Ltd.
OTCGREY:ERYTF
|
USA | $107.74K |
|
Velocity Composites plc
LSE:VEL
|
UK | GBX5.16 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down NeuroThera Labs Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeuroThera Labs Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeuroThera Labs Inc. (2022–2025)
The table below shows the annual total liabilities of NeuroThera Labs Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | CA$156.00K | +277.61% |
| 2024-01-31 | CA$41.31K | +351.50% |
| 2023-01-31 | CA$9.15K | -48.15% |
| 2022-01-31 | CA$17.65K | -- |